韩国复发或难治性弥漫大B细胞淋巴瘤患者治疗模式、生存率与医疗费用的全国性分析数据表

数据集获取（Figshare）

• 源站标题：DataSheet_1_A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma.docx
• DOI：10.3389/fonc.2024.1282323.s001
• 发布日期：2024-02-01
• 文件数：1 个
• 文件总体积：746.40 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_A_nationwide_analysis_of_the_treatment_patterns_survival_and_medical_costs_in_Korean_patients_with_relapsed_or_refractory_diffuse_large_B-cell_lymphoma_docx/25123697

命令行下载

curl -L -o "DataSheet_1_A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large .docx" "https://ndownloader.figshare.com/files/44346275"

文件清单

• DataSheet_1_A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large .docx（746.40 KB）

文件总体积 746.40 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundApproximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to treatment or experience relapse after initial therapy. Unfortunately, treatment options for older patients and those who experience relapse or become refractory to hematopoietic stem cell transplantation (HSCT) are limited. This nationwide population-based study aimed to identify treatment patterns, survival times, and treatment costs in patients with relapsed/refractory DLBCL (R/R DLBCL).
Materials and methodsBetween 2011 and 2020, data on patients with R/R DLBCL were retrieved from the Korean Health Insurance Review & Assessment Service, encompassing the entire population. We identified the treatment patterns for each treatment line using a Sankey diagram and calculated the median time to the subsequent treatment in line. Median overall and progression-free survival times were estimated using the Kaplan–Meier survival curves. Finally, the medical costs incurred during DLBCL treatment were calculated for each treatment line and the costs related to HSCT were summarized at the episode level.
ResultsA total of 864 patients with R/R DLBCL who received second-line treatment were identified, and a regimen of ifosfamide, carboplatin, and etoposide (ICE) was administered the most. Among them, 353 were refractory or relapsed cases that were treated with third-line treatments. The median times for second-line to third-line, third-line to fourth-line, fourth-line to fifth-line, and fifth-line to sixth-line treatment failures gradually decreased (3.93, 2.86, 1.81, and 1.38 months, respectively). The median overall survival time was 8.90 and 4.73 months following the second-line and third-line treatments, respectively. In the third-line treatment setting, the patients did not show a significant difference in survival time after HSCT. The median medical cost was $39,491 across all treatment lines including the cost of HSCT which was $22,054.
ConclusionThe treatment patterns in patients with R/R DLBCL, especially at third-line treatments and thereafter, were complicated, and their prognosis was poor despite the high medical costs. Novel and effective treatment options a

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2024.1282323.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_A_nationwide_analysis_of_the_treatment_patterns_survival_and_medical_costs_in_Korean_patients_with_relapsed_or_refractory_diffuse_large_B-cell_lymphoma_docx/25123697）。